---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-061512"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:44:49.734510+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Phathom reports Q4/FY2023 results; VOQUEZNA launch nets $0.7M revenue, cash runway extended to 2026

## Summary
- Q4 net revenue $0.7M from VOQUEZNA launch; cumulative prescriptions over 14,000 as of Feb 23, 2024.
- Expanded term loan facility up to $300M with more favorable terms; access to $160M additional; cash runway through 2026.
- Express Scripts added VOQUEZNA to formularies; ~60M commercial lives covered (~38% of U.S. commercial).
- FDA accepted NDA for Non-Erosive GERD; PDUFA July 19, 2024; launch expected upon approval.
- Net loss Q4 $79.6M ($46M non-GAAP adjusted); G&A up due to commercial build and stock-based comp.

## SEC filing metadata
- accession: 0001193125-24-061512
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312524061512/0001193125-24-061512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312524061512/d759734d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-061512
- JSON: https://secwatch.observer/filing/0001193125-24-061512.json
- Plain text: https://secwatch.observer/filing/0001193125-24-061512.txt

## Key facts
- Earnings Releases
  Phathom Pharmaceuticals, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $0.7 million.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Revenue: $0.7 million
  - Result: reported results
  source text: Business Update • Launched VOQUEZNA ® (vonoprazan) tablets in November 2023 for the treatment of Erosive GERD (gastroesophageal reflux disease), achieving net revenues of $0.7 million for the fourth quarter • Early physician prescribing demonstrates strong demand for VOQUEZNA • Secured expanded commercial coverage for VOQUEZNA with a top U.S. pharmacy benefit
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783183/000119312524061512/0001193125-24-061512-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.